CMS Denies Lilly’s Request For Broad Medicare Coverage Of Amyvid In Draft Memo
This article was originally published in The Pink Sheet Daily
Executive Summary
Medicare would only cover beta amyloid positron emission tomography in diagnosing dementia, relying on Lilly’s imaging agent, as part of a clinical trial, according to a proposed decision memo.
You may also be interested in...
Medicare Coverage Decision For Amyvid Due July 2013
At Lilly’s request, CMS has agreed to consider expanding the positron imaging tomography tracers that can be covered by Medicare to include agents for imaging beta-amyloid plaques when diagnosing dementia and other neurodegenerative disease.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Deal Watch: Sanofi, Boehringer Swap Side Businesses
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.